Improving Diversity In Clinical Trials

The lack of diversity in clinical trials isn’t a new problem, but in 2020 this issue rose to the forefront of the industry as a spotlight was cast on drug development as a whole due to the COVID pandemic. In fact, a key milestone related to this topic came in November 2020 when the FDA issued its final guidance, Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs. The experts in this ebook come from varying backgrounds, and as such, offer a myriad of recommendations relating to improving clinical trial enrollment of racial and ethnic minority groups.

Companies To Watch: 2020

In 2020 we profiled 11 biopharma companies in our Companies To Watch section. These companies focused on a range of therapeutics including antifungals, antibody therapeutics for immunological diseases, and multiple antivirals and vaccines related to COVID-19. 

Patent Issues In Life Sciences: An Overview of Legal Coverage Of The Topic

From IPR trends, to new advances in AI or medtech, to how you can protect your company from a legal perspective, patent issues are, in some way, likely on your mind as a biopharma executive. For this ebook we’ve gathered some of the most informative and educational patent-related articles that appeared in Life Science Leader during 2019 and early 2020.

Companies To Watch: 2019

The Life Science Leader Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons. In 2019 we profiled 10 biopharma companies in this section. These companies focused on a range of therapeutics including antimicrobials, cell & gene therapies, and antibiotic resistance.

How AI Is Transforming The Life Science Sector - Part 1

There’s no doubt that AI has great potential in life sciences, from R&D through to commercialization. The challenge is seeing through all of the hype. That’s why we’ve gathered some recent articles on this topic that identify specifics regarding what can be done in this emerging field as it pertains to the biopharma industry and what companies have become early adopters.

How AI Is Transforming The Life Science Sector - Part 2

There’s no doubt that AI has great potential in life sciences, from R&D through to commercialization. The challenge is seeing through all of the hype. That’s why we’ve gathered some recent articles on this topic that identify specifics regarding what can be done in this emerging field as it pertains to the biopharma industry and what companies have become early adopters.

The 2018 Biopharma Manufacturing Ebook

Become better at your biopharma manufacturing job by seeing how some of your peers deal with everything from consent decrees to problems with a CDMO to the need for more engaged employees on the plant floor.